Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy

Kaplan, Allen P.; Ledford, Dennis K.; Ashby, Mark; Canvin, Janice; Zazzali, James L.; Conner, Edward; Veith, Joachim; Kamath, Nikhil; Staubach, Petra; Jakob, Thilo; Stirling, Robert; Kuna, Piotr; Berger, William; Maurer, Marcus; Rosén, Karin

doi:10.1016/j.jaci.2013.05.013

Cited by 488 publications

(601 citation statements)

References 22 publications

Supporting

Mentioning

510

Contrasting

Unclassified

Order By: Relevance

“…Before 2014, there were few case reports on efects of omalizumab used; although not indicated in patients with chronic urticaria, few studies on patients' experiences with omalizumab and omalizumab phase studies in larger groups of patients; however, there is still a limited number of studies on the use of omalizumab for the treatment of CSU in a real life context [4].…”

Section: Omalizumab Therapy In Csumentioning

confidence: 99%

“…More than 5 million people only in Europe sufer from CSU, especially its negative efects are on quality of life and sleep, school and work performance and daily life activities, and social relationships [3]. Recently, inside the EAACI/GA(2) LEN/EDF/WAO Guideline, it has been endorsed that nonsedating H1 antihistamines ought to be used for the irst-line treatment of CSU and doses of H1 antihistamines can be increased by four-fold as the second-line treatment till symptoms can be kept under control completely [1,4]. When these increased doses of H1 antihistamines fail, one of the recommended therapies as the third-line treatment is omalizumab.…”

Section: Introductionmentioning

confidence: 99%

“…When these increased doses of H1 antihistamines fail, one of the recommended therapies as the third-line treatment is omalizumab. It is the only available agent of anti-immunoglobulin E (IgE) at the current time [3,4].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Anti IgE Therapy in Chronic Urticaria

Ertaş¹

2017

A Comprehensive Review of Urticaria and Angioedema

View full text Add to dashboard Cite

The crucial position of IgE within the pathogenesis of allergic diseases made it a key target for therapy. The inhibition of the allergic inlammatory cascade by anti-immunoglobulin E (IgE) therapy is a new and promising concept in the treatment of these diseases. Currently available anti-IgE agent omalizumab has been started to be used in past 3 years in the cases of chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CINDU), resistant to the irst-, second-, and some third-line treatments. The use of omalizumab as an efective and safe biological therapy for inadequately controlled severe, persistent patients with CSU and CINDU provided a valuable new treatment option for these patients. However, the data about possible mechanisms of anti-IgE therapy in these patients, treatment strategies and dose regimens of anti-IgE therapy are diferent, and special patient groups and possible side efects are still insuicient. Also, studies about possible future anti-IgE treatment options are ongoing in CSU.

show abstract

Section: Omalizumab Therapy In Csumentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Anti IgE Therapy in Chronic Urticaria

Ertaş¹

2017

A Comprehensive Review of Urticaria and Angioedema

View full text Add to dashboard Cite

show abstract

“…Az anti-IgE antitesteket tartalmazó omalizumab nagy betegszámú, randomizált placebo kontrollált vizsgálatokban bizonyult hatékonynak H1 antihisztamin kezelésre refrakter krónikus spontán urticariában (3,4,5). Az anti-IgE terápia során elsôként a szabad IgE szint csökken, majd ennek hatására a nagy affinitású IgE receptorok száma (FcεRI), így az anti-FcεRI és anti-IgE autoantitestek nem képesek keresztkötést létesíteni.…”

Section: Megbeszélésunclassified

Omalizumab treatment in patients with chronic spontaneous urticaria

Hidvégi¹

2015

BVSZ

View full text Add to dashboard Cite

ÖSSZEFOGLALÁSA szerzô krónikus spontán urticariás betegek omalizumab (anti-IgE antitest) Key words: chronic spontaneous urticaria -omalizumabA krónikus spontán urticaria a populáció 0,1%-ában jelentkezô, gyakran évtizedekig perzisztáló, polietiológiás, jelentôs életminôség károsodást eredményezô betegség. A tünetek hat héten túl szinte mindennap jelentkeznek, 50%-ban angiooedema is jelentkezik, indukálható urticaria, urticaria vasculitis kizárható. Etiológiai tényezôként ételin-tolerancia, infekciók és autoimmun mechanizmus merül-het fel. A báziskezelésként alkalmazott H1 antihisztamin gyakran ineffektív, az új nemzetközi javaslatnak megfelelôen fokozatosan emelve akár négyszeres dózisemelés is megengedett az ún. nem szedáló antihisztaminokból, illetve harmadik terápiás lépcsôben az emelt dózisú H1 antihisztamin omalizumab (anti-IgE monoklonalis antitest) cyclosporine vagy leukotrién antagonista adással egészít-hetô ki. Rövid ideig szisztémás kortikoszteroid adása is szükséges lehet (1). A közleményben a Semmelweis Egyetem Bôr-, Nemikórtani és Bôronkológiai Klinikán gondozott betegek omalizumab kezelésével szerzett elsô tapasztalatok kerülnek ismertetésre. Betegek és módszerekKrónikus spontán urticariában szenvedô betegek (4 nô, 1 férfi) a tünetek fennállásának idôtartama 1-6 évig terjedô, minden beteg urticariáját angiooedema is kísérte. Három beteg anamnaesisében rhinitis allergica és/vagy asthma bronchiale, 2 betegnél szubsztituált hypothyreosis szerepelt, 2 beteg esetén NSAID, 1 esetben ACE-inhibitor provokálta az urticariát. A tünetek ezek elhagyása után is fennmaradtak. A rutin laboratóriumi paraméte-rek normál tartományban voltak vagy klinikailag nem szignifikáns eltérést mutattak a vizsgált betegekben. Gasztroenterológiai kivizsgálás részeként 3 esetben igazolódott Helicobacter pylori asszociált gastritis, eradikációs kezelést a betegek megkapták. In-124

show abstract

“…Tedaviye dirençli kronik ürtikerde omalizumab kullanımı son yıllarda giderek yaygınlaşmaya başlamıştır [1][2][3][4] . Kronik ürtiker tedavi klavuzunda 2012 yılının sonunda yapılan son revizyona göre ikinci kuşak antihistamin ilaçların dört katına kadar çıkılan dozlarına yanıt vermeyen olgularda üçüncü basamak tedavide siklosporin A, lökotrien reseptör antagonisti ilaçlar gibi omalizumab kullanımı da önerilmektedir 5 .…”

Section: Introductionunclassified

Omalizumab and treatment-resistant chronic spontaneous urticaria

Akyol¹,

Öktem²,

Akay³

et al. 2015

TURKDERM

View full text Add to dashboard Cite

Background and Design: Humanized monoclonal antibody omalizumab was developed for the treatment of moderate-to-severe asthma. However, recently, reports on the successful use of omalizumab in the treatment of resistant chronic urticaria are increasing in the literature. Materials and Methods: We retrospectively evaluated treatment response, adverse effects and duration of remission in 13 chronic spontaneous urticaria patients treated with omalizumab between May 2010 and January 2014. Results: In ten of the thirteen patients treated with omalizumab, urticarial lesions were suppressed and no side effects were observed. Conclusion: Our observations support the findings in the literature indicating that omalizumab is an effective and safe option in the management of treatment-resistant chronic urticaria. (Turkderm 2015; 49: 180-3)

show abstract

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy

Cited by 488 publications

References 22 publications

Anti IgE Therapy in Chronic Urticaria

Anti IgE Therapy in Chronic Urticaria

Omalizumab treatment in patients with chronic spontaneous urticaria

Omalizumab and treatment-resistant chronic spontaneous urticaria

Contact Info

Product

Resources

About